125 research outputs found
ãã©ã³ã¹ãžã§ããã¯ããŠã¹ã¢ãã«ãçšããèçºããå¶åŸ¡ååã®ç 究
æ
¢æ§èçããèãããžé²å±ããBåèçãŠã€ã«ã¹è¡šé¢æåã®ãã©ã³ã¹ãžã§ããã¯ããŠã¹ã¢ãã«ãçšããŠãèçºããã®ç
æ
æ©åºã解æãããšãšãã«ãçºãããå¶åŸ¡ããååã®ã¹ã¯ãªãŒãã³ã°ãé²ãããæ€èšçµæã¯ã以äžã®ããšãã§ããã1)èçºããã®ç
æ
ã®æ€èšãšããŠãèçã®èªå°ã®éã«è¡ãåçš®ã®çŽ°èå
ç«åŠçæäœã«ãã£ãŠãåããç¶æ
ã®ç°åœ¢æ§ãå€åãçºããçã«éããçããããšãåãã£ããç°ãªããªã³ãçåç»ã«ãã£ãŠèªå°ããæ
¢æ§èçã芳å¯ãããšãããCD8+Tãªã³ãçãCD4+Tãªã³ãçãB(CD19+)ãªã³ãçã®é ã«èçµç¹ã®ç°åœ¢æ§ã®çšåºŠãçºããç(ããããã86%ã24%ã0%)ã«å¯äžããŠããããšãæããã«ãªã£ã(Cancer Res.64:3326,2004)ã2)ãããŸã§è现èé害ã«éèŠãªFasãªã¬ã³ã(FasL)ãä»ããçµè·¯ãæå¶ãããšãèçã軜快ãçºãããèæã«æžå°ãããšããçµæãåŸãŠããã®ã§(J.Exp.Med.196:1105,2002)ãFasLæäœã®æäžã«ãã圱é¿ãçŽ2äžåã®éºäŒå解æãå¯èœã§ããDNAããããçšããŠæ€èšãããæäœã®æäžã«ãã£ãŠ352éºäŒå(1.7%)ã®çºçŸãææã«å€åããŠãã(P<0.05)ããã®ãã¡æ©èœãäºæž¬ãããéºäŒåã190åèªããããããªãã§ãã现èæ»ã»å¢æ®å åã«é¢ããéºäŒå矀ã®å€åã4.7%ãšæãé«çã§ãã£ãã3)çºããã«é¢é£ããåè£éºäŒåã®1äŸãšããŠãã»ãªã³ã»ã¹ã¬ãªãã³ãããŒãŒpim-3ã®è§£æãè¡ãããšã«ãã£ãŠã现èå¢æ®ãä¿é²ãã¢ãããŒã·ã¹(现èæ»)ãæå¶ããŠèããã®é²å±ã«é¢äžããŠããããšã瀺åããã(Int.J.Cancer 114:209,2005)ããããã®çµæãããçºããç
æ
ã®çŽ°èå
ç«åŠçç¹åŸŽãæããã«ãªããšãšãã«ãçºããéçšã«é¢äžããéºäŒåã®ã¹ã¯ãªãŒãã³ã°ãç¶ç¶ããããšã«ãã£ãŠèçºããã®å¶åŸ¡ã«æçšãªéºäŒåãçµã蟌ãŸããå¯èœæ§ã瀺ããããHepatocellular carcinoma (HCC) is a common complication of chronic viral hepatitis. Recently, we have reported that Fas ligand (FasL) is critically involved in the induction of chronic immune-mediated liver cell injury that increases HCC incidence (J Exp Med 196 : 1105, 2002) ; however, the molecular mechanisms potentially responsible for carcinogenesis are not well defined. In the current study, we asked the regulatory molecules in liver diseases that displayed different procarcinogenic potentials in a hpatitis B virus (HBV) transgenic mouse model. The results are summarized as follows.1)Transfer of CD8^+-enriched splenocytes caused prolonged disease kinetics and a marked increase in the extent of hepatocyte apoptosis and regeneration. In 12 out of 14 mice the transfer resulted in multiple hepatocellular carcinomas (HCCs) comparable to the manifestations seen in the mice transferred with total splenocytes. In contrast, mice that had received CD4^+-enriched cells demonstrated lower lev els of liver disease and developed fewer incidences of HCC (4 of 17). The experiment also revealed that all the groups of mice complicated with HCC developed comparable mean numbers and sizes of tumors. B cell depletion had no effect on disease kinetics in this model. (Cancer Res. 64 : 3326, 2004)2)During more than twelve months of disease progression, 352 (1.7 % of all) genes were expressed differentially between the mice treated with anti-FasL Ab and with PBS (P<0.05), 190 genes of which were assigned to functional groups based on Gene Ontology categories. In the gene groups of enzymes, cell communication, cellular components, signal transduction, and nucleic acid binding, the significant changes due to anti-FasL Ab treatment were observed in 43(1.6% of the gene group), 42(2.0%), 31(1.3%), 28(1.4%), and 22(1.8%) genes, respectively. In the cell communication group, high proportion (4.3%) of cell death control genes was involved in this expression dynamics.3)We identified several genes expressed differentially at the pre-malignant lesions. Among these genes, we focused on Pim-3, which is reported as a member of a proto-oncogene Pim family, but its contribution to hepatocarcinogenesis remains elusive. The mRNA expression was selectively detected in human hepatoma cell lines, but not in normal liver tissues. Pim-3 protein was also expressed in human hepatocellular carcinoma tissues and cell lines but not in normal hepatocytes. Moreover, cell proliferation was attenuated in human hepatoma cell lines, HepsB and HuH7, by RNA interference ablation of Pim-3 gene expression. (Int.J.Cancer 114 : 209, 2005)Taken together, these data suggest the molecular mechanisms potentially responsible for hepatocarcinogenesis and the future studies for the development of molecular targets.ç 究課é¡/é åçªå·:15590631, ç 究æé(幎床):2003-2004åºå
žïŒããã©ã³ã¹ãžã§ããã¯ããŠã¹ã¢ãã«ãçšããèçºããå¶åŸ¡ååã®ç 究ãç 究ææå ±åæžã課é¡çªå·15590631 (KAKENïŒç§åŠç 究費å©æäºæ¥ããŒã¿ããŒã¹ïŒåœç«æ
å ±åŠç 究æïŒ)ãããæ¬æããŒã¿ã¯èè
çå ±åæžããäœ
æ ¢æ§èçãèªå°ããçºããé¢é£éºäŒåã®åå®
é沢倧åŠéå±ç
é¢æ
¢æ§ãŠã€ã«ã¹èçããã®çºãããèªå°ãã責任éºäŒåãåå®ããããšãç®çã«ãããŠã¹ã¢ãã«ã«ãããŠçºããçã®ç°ãªãèçµç¹ã®éºäŒåçºçŸãããã¡ã€ã«ãæ¯èŒããããšã«ãã£ãŠåè£éºäŒåãéžæãããèçºããã¢ãã«ã¯ãBåèçãŠã€ã«ã¹(HBV)ãã©ã³ã¹ãžã§ããã¯ããŠã¹ã«ãŠã€ã«ã¹æåç¹ç°çãªå
ç«åå¿ãèªå°ããããšã«ãã£ãŠã17ãµæéã®çµéã®äžã§æ
¢æ§èçããç°åœ¢æ§ã䌎ã£ãåããç¶æ
ãçµãŠ90%以äžã®ããŠã¹ã«è现èãã(èãã)ãçºçããå®éšç³»ã確ç«ããŠãããæ
¢æ§èçã®èªå°ã«é¢ããŠã¯ããããŸã§å ±åããèé害ååã§ããFasãªã¬ã³ã(FasL)ã®é¢äžã«å ããŠããªã³ãçåç»ã«ãããCD8+ Tãªã³ãçãæ·±ãé¢äžããŠãããçºããç(çºããããã³ã·ã£ã«)ã亢é²ããŠããããšãåãã£ãããããã®æ€èšã§åŸãããçºããçã®ç°ãªãåããç¶æ
(éè
«çéš)ã®èçµç¹ã«ã€ããŠãéºäŒåçºçŸãããã¡ã€ã«ãæ¯èŒããããšã«ãããçºããçã®å€åã«å¿ããŠ352éºäŒå(1.7%)ã®çºçŸãææã«å€åããããšãåãã£ã(P<0.05)ããªãã§ãã现èæ»ã»å¢æ®å åã«é¢ããéºäŒå矀ã®å€åã4.7%ãšæãé«çã§ãã£ããããã«ãçºããã«é¢é£ããåè£éºäŒåã®1äŸãšããŠãã»ãªã³ã»ã¹ã¬ãªãã³ãããŒãŒpim-3ã®è§£æãè¡ãããšã«ãã£ãŠã现èå¢æ®ãä¿é²ãã¢ãããŒã·ã¹(现èæ»)ãæå¶ããŠèããã®é²å±ã«é¢äžããŠããããšã瀺åããããç 究課é¡/é åçªå·:16021216, ç 究æé(幎床):2004åºå
žïŒãæ
¢æ§èçãèªå°ããçºããé¢é£éºäŒåã®åå®ãç 究ææå ±åæžã課é¡çªå·16021216ïŒKAKENïŒç§åŠç 究費å©æäºæ¥ããŒã¿ããŒã¹ïŒåœç«æ
å ±åŠç 究æïŒïŒïŒhttps://kaken.nii.ac.jp/ja/grant/KAKENHI-PROJECT-16021216/)ãå å·¥ããŠäœ
ãã©ã³ã¹ãžã§ããã¯ããŠã¹ã¢ãã«ãçšããèçºçã®ååå ç«åŠçäºé²æ³ã®ç 究
é沢倧åŠéå±ç
é¢èçºçã¢ãã«ã«ãããŠãæ
¢æ§èçã®çµéãçµç¹åŠçã«èŠ³å¯ãããšã移æ€9ã«æåŸã«è现èã®ç°åœ¢æ§ãåºçŸãã17ã«æåŸã«100%(12/12)ã«èè
«çãçºçãããFasLãä»ããçµè·¯ãæå¶ããç®çã§ãèçã®çµéäžã«FasLã®äžåæäœãæäžãããšä»¥äžã®å€åãèªãã(J.Exp.Med.196: 1105,2002)ãa)è¡æž
ãã©ã³ã¹ã¢ãããŒãŒå€ãããèçã®ããŒã¯ã¯1/3ã«è»œå¿«ãããb)FasLã«ãã掻æ§åãããè现èå
ã®caspase-3ã¯ã1/4ã«äœäžããŠãããc)è现èã®ã¢ãããŒã·ã¹ãTUNELã¢ãã»ã€ã«ãã解æãããšã1/5ã«äœäžããŠãããd)è现èã®åçå¢æ®ãPCNAæè²ã«ããæ€èšãããšã1/3ã«æžå°ããŠãããe)èçµç¹ã«æµžæœ€ããŠããåæ žçæ°ãæåç¹ç°çTãªã³ãçã®å²åã«å€åã¯ãªãã£ããf)èççºçåŸ7ã23ãµæéã®èŠ³å¯æéäžã«çºçããèè
«çã¯ã13%(2/15,P<0.0001)ã«æžå°ããããããããèçºçã¢ãã«ã«FasLäžåæäœãæäžããããšã«ãã£ãŠãèãžã®çç现èã®æµžæœ€ã«ã¯åœ±é¿ããªããã®ã®FasLãä»ããã·ã°ãã«çµè·¯ãçŽæ¥æå¶ãããŠãèçã軜æžãããšãšãã«è现èã®ã¢ãããŒã·ã¹åã³åçå¢æ®ãäœäžããèçã®çºçãæžå°ããããšã瀺ããããç 究課é¡/é åçªå·:13770259, ç 究æé(幎床):2001-2002åºå
žïŒããã©ã³ã¹ãžã§ããã¯ããŠã¹ã¢ãã«ãçšããèçºçã®ååå
ç«åŠçäºé²æ³ã®ç 究ãç 究ææå ±åæžã課é¡çªå·13770259ïŒKAKENïŒç§åŠç 究費å©æäºæ¥ããŒã¿ããŒã¹ïŒåœç«æ
å ±åŠç 究æïŒïŒ ïŒ https://kaken.nii.ac.jp/ja/grant/KAKENHI-PROJECT-13770259/ ïŒãå å·¥ããŠäœ
CåèçãŠã€ã«ã¹ã«ãããè¡šé¢æåæ€åºç³»ã®ç¢ºç«: é«å€ç°é åã®é¢äžã«ã€ããŠ
ååŸåŠäœ : å士ïŒå»åŠïŒ, åŠäœæäžçªå· : å»åç²ç¬¬1076å·, åŠäœæäžå¹Žææ¥ïŒå¹³æ5幎3æ25æ¥,åŠäœæäžå¹ŽïŒ199
ããŒã«ãŒéºäŒåãçšããèãã现èã®èµ·æºãšååæ©æ§ã®è§£æ
é沢倧åŠéå±ç
é¢èãã现èã®èµ·æºãšãªãå¯èœæ§ããã骚é«åã³è现èã®ããŒã«ãŒéºäŒåãçšããããšã«ãã£ãŠ,ãã®åæ
ãin vivoã§æ¢çŽ¢ãããšãšãã«çºããã«è³ãååæ©æ§ã®è§£æãç®çãšãããæšå¹ŽåºŠã«åŒãç¶ããŠ,ããŒã«ãŒéºäŒåããã£ã骚é«çŽ°èã«ãã£ãŠæ
¢æ§èçã¢ãã«ãæ§æããããšã«ãã£ãŠ,è现èã®åæ§ç¯ã«ããã骚é«çŽ°èã®é¢äžã芳å¯ãããšãšãã«,æ
¢æ§èçã®éçšã§åºçŸããŠããèãã现èã骚é«çŽ°è,è现è,ãŸãã¯äž¡è
ã®èå现èã®ãããã«ç±æ¥ããããæ€èšããã1)æ
¢æ§èçã¢ãã«ã®äœæ:DiethylnitrosamineååŠçºããã¢ãã«(â)(Lab.Invest.85:655,2005)ã«ãããŠ,æŸå°ç·ç
§å°(900 cGy)ããã®ã¡ã«å系統(C57BL/6)ã®GFPéºäŒåå°å
¥ããŠã¹(â)ã®éªšé«çŽ°è(10^7å)ã移æ€ããŠéªšé«ã®åæ§ç¯ãè¡ã£ãã(2)æ
¢æ§èççµç¹ã®è§£æ:éèåãäžå¿ã«éªšé«çŽ°èãšèèç±æ¥çŽ°èã®èåãèµ·ãã£ãŠããããšã芳å¯ããã(3)èããçµç¹ã®è§£æ:骚é«ç±æ¥GFPéœæ§çŽ°èã¯,Cytokeratinéœæ§ã®è管ç±æ¥ãã现èãAlbuminéœæ§ã®èç±æ¥ãã现èãšç°ãªã£ãŠããããããŠ,骚é«ç±æ¥çŽ°èã®äžéšã¯PCNAéœæ§ã®å¢æ®èœã®é«ã现èã§ãããã®ã®,ãã现èã«ç¹åŸŽçãªÎ²-cateninã®æ žç§»è¡ã¯èªãã,é質ãæ§æãã现èã«ååããŠãããã®ãšèããããããããã,èãã现èãçŽæ¥çã«éªšé«çŽ°èããç±æ¥ããéçšã¯èŠ³å¯ãããªãã£ãã,骚é«ç±æ¥çŽ°èã¯ããçµç¹ã®é質(ç·ç¶èœçŽ°è,è管,çç现èãªã©)ã«ååããŠ,çºããã®åŸ®å°ç°å¢ã«é¢äžãã§ããå¯èœæ§ã瀺åããããç 究課é¡/é åçªå·:18659206, ç 究æé(幎床):2006 â 2007åºå
žïŒãããŒã«ãŒéºäŒåãçšããèãã现èã®èµ·æºãšååæ©æ§ã®è§£æãç 究ææå ±åæžã課é¡çªå·18659206ïŒKAKENïŒç§åŠç 究費å©æäºæ¥ããŒã¿ããŒã¹ïŒåœç«æ
å ±åŠç 究æïŒïŒïŒhttps://kaken.nii.ac.jp/ja/grant/KAKENHI-PROJECT-18659206/)ãå å·¥ããŠäœ
ãã©ã³ã¹ãžã§ããã¯ããŠã¹ã¢ãã«ãçšãããŠã€ã«ã¹æ§èçºçã®ååæ©æ§ã«é¢ããç 究
é沢倧åŠéå±ç
é¢æ
¢æ§ãŠã€ã«ã¹èçããã®èçºçã«é¢äžãããŠã€ã«ã¹åŽã宿䞻åŽèŠå ãæããã«ããç®çã§ãããŠã¹ã¢ãã«ãçšããŠæ€èšãããBåèçãŠã€ã«ã¹ãã©ã³ã¹ãžã§ããã¯ããŠã¹ã«ãå系統ã®éçåããŠã¹ãã骚é«çŽ°èãèŸçŽ°èã移æ€ããããšã«ãã£ãŠæ
¢æ§èçã¢ãã«ãäœæãããèçã®çµéã芳å¯ãããšãçŽ17ã«æåŸã«è现èçãçºçãã(J.Exp.Med.188:341,1998)ã1.ãŠã€ã«ã¹åŽèŠå ã®æ€èšãšããŠãèçµç¹ã«ããããŠã€ã«ã¹éºäŒåã®çºçŸãRNAãã¿ã³ãã¯ã¬ãã«ã§æ€èšãããšãåçç¶æ
ãéççµç¹ã«ãããçºçŸã¯ããäœãã¬ãã«ãªããæç¶ããŠãããççµç¹ã«ããããŠã€ã«ã¹éºäŒåã®çºçŸã¬ãã«ã«ã¯å€æ§æ§ãèªãããŠã€ã«ã¹éºäŒåãŸãã¯çºçŸèª¿ç¯å åã®å€ç°ã瀺åãããã2.宿䞻åŽèŠå ã®æ€èšãšããŠã移æ€ããèŸçŽ°èãCD4ãŸãã¯CD8éœæ§Tãªã³ãçãBãªã³ãçãåçã®ååç»ã«åé¢ããŠåœ¹å²ãæ€èšãããšãããäž»ã«CD8éœæ§Tãªã³ãçãæ
¢æ§èçã®å¢æªããã³é·å»¶åã«äœçšããŠãããããã§èšåºå¿çšã念é ã«ãCD8éœæ§Tãªã³ãçã®çŽ°èé害äœçšãæå¶ããç®çã§ããšãã§ã¯ã¿ãŒååã§ããFasãªã¬ã³ãã«å¯Ÿããäžåæäœãæäžãããšãããæ
¢æ§èçãæå¶ããèçºçãèæã«æžå°ããããããããèçºçéçšã«ã¯ä»¥äžã®ãŠã€ã«ã¹åŽã宿䞻åŽèŠå ã®é¢äžã瀺åããããç 究課é¡/é åçªå·:11770270, ç 究æé(幎床):1999-2000åºå
žïŒããã©ã³ã¹ãžã§ããã¯ããŠã¹ã¢ãã«ãçšãããŠã€ã«ã¹æ§èçºçã®ååæ©æ§ã«é¢ããç 究ãç 究ææå ±åæžã課é¡çªå·: 11770270ïŒKAKENïŒç§åŠç 究費å©æäºæ¥ããŒã¿ããŒã¹ïŒåœç«æ
å ±åŠç 究æïŒïŒ ïŒ https://kaken.nii.ac.jp/ja/grant/KAKENHI-PROJECT-11770270/ïŒãå å·¥ããŠäœ
ãã©ã³ã¹ãžã§ããã¯ããŠã¹èçºçã¢ãã«ã«ãããæšçååã®åå®
é沢倧åŠéå±ç
é¢æ
¢æ§ãŠã€ã«ã¹èçããã®èçºçãå¶åŸ¡ããæšçååãåå®ããããšãç®çã«ãçºçã«é¢é£ããããšãäºæ³ããã现èæ»ã·ã°ãã«ã®ãªãã§Fas/Fasãªã¬ã³ã(FasL)ãä»ããåŸè·¯ã«æ³šç®ããŠæ€èšãããåæã«ãæ°ããªæšçååã®äŸ¯è£ãã¹ã¯ãªãŒãã³ã°ãããèçºçã¢ãã«ã¯ãBåèçãŠã€ã«ã¹(HBV)ãã©ã³ã¹ãžã§ããã¯ããŠã¹ã«ãŠã€ã«ã¹æåç¹ç°çãªå
ç«åå¿ãèªå°ããããšã«ãã£ãŠãæ
¢æ§èçãè现èç(èç)ãçºçããå®éšç³»ã確ç«ããŠããã1.èçã®çµéäžã«ãFasLã®äžåæäœãæäžãããšãèçã®ããŒã¯ã¯1/3ã«è»œå¿«ããããŸããå
ç«çµç¹åŠçæ€èšã«ãããŠè现èã®ã¢ãããŒã·ã¹ãåçå¢æ®ãäœäžããŠãããèçã®çºçã¯å¯Ÿç
§çŸ€ã®100%ã«æ¯ã¹ãŠ13%(P<0.0001)ãšèæã«æžå°ããããããããæ
¢æ§èçã«ãããŠãFasLãä»ããè现èæ»ã·ã°ãã«ãå¶åŸ¡ããããšã«ãã£ãŠãèçºçãææ¢ãããå¯èœæ§ã瀺åãããã2.çºçéçšã«ãããéºäŒåçºçŸãã¿ãŒã³ã®å€åããã£ãã¡ã¬ã³ã·ã£ã«ãã£ã¹ãã¬ã€(DD)æ³ãçšããŠæ€èšãããšãããåçç¶æ
ã§çºçŸãå¢å ããŠããéºäŒåã¯ãæ©èœãæªç¥ãªãã®ã6çš®é¡ãæ¢ç¥éºäŒåã19çš®é¡ã§ãã£ããäžæ¹ãæžå°ããŠãããã®ã¯æ¢ç¥éºäŒåã19çš®é¡èªãããããç 究課é¡/é åçªå·:14026016, ç 究æé(幎床):2002åºå
žïŒããã©ã³ã¹ãžã§ããã¯ããŠã¹èçºçã¢ãã«ã«ãããæšçååã®åå®ãç 究ææå ±åæžã課é¡çªå·14026016ïŒKAKENïŒç§åŠç 究費å©æäºæ¥ããŒã¿ããŒã¹ïŒåœç«æ
å ±åŠç 究æïŒïŒïŒhttps://kaken.nii.ac.jp/ja/grant/KAKENHI-PROJECT-14026016/)ãå å·¥ããŠäœ
- âŠ